To the Editor: A closer look at the sky-rocketing costs of the category of drugs known as specialty pharmaceuticals validates a proposal to rein them in, offered by TWU Local 100 President Tony Utano, in contract talks with the MTA.
Let’s look at the differences between ‘traditional’ & ‘specialty’ drugs to understand the astronomical gap in prices between these two groups.
This item is available in full to subscribers.
We have recently launched a new and improved website. To continue reading, you will need to either log into your subscriber account, or purchase a new subscription.
If you have an active digital subscription, then you already have an account here. Just reset your password, if you've not yet logged in to your account on this new site.
If you are a current print-only subscriber, and want access to our website,click here to view your options for changing you subscription level.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
